

Introduction

The Biomodulatory Materials Engineering Laboratory has been working to develop a cheaper and more widely applicable solution to nonunion bone fractures than currently available. Restricted supply and possible immune response to bone grafts limit their applications¹, and other new regenerative engineering treatments have proven too expensive and patient-specific for broad clinical implementation².



Bone tissue regeneration is complex because the tissue contains not only osteoblasts, but a blood vessel and nerve network as well³. Each of these cell types can be encouraged to grow by a different simple signaling molecule^{4,5}. This project focuses on the use of hydrogen peroxide (H_2O_2) for the vascularization of regenerated bone tissue.



Objectives

- Determine the therapeutic window of hydrogen peroxide for the differentiation of mesenchymal stem cells into endothelial cells using
- Synthesize a novel biomaterial which releases hydrogen peroxide within the determined therapeutic window





Based on results from both the inductivity and cytotoxicity tests, the therapeutic window of hydrogen peroxide for the differentiation of endothelial cells from mesenchymal stem cells has an upper limit of 300 μ M. Concentrations of hydrogen peroxide as low as 2 µM are still angioinductive.

Hydrogen peroxide releasing biomaterials for vascularization in bone tissue regeneration

Mollie J. Harrison, Brittany N. Allen, and Bret D. Ulery

Department of Biomedical, Biological, and Chemical Engineering University of Missouri



of therapeutic window and complete the synthesis of the novel biomaterial. Then we will perform release tests on the biomaterial to determine its hydrogen peroxide release profile, test its biocompatibility and inductivity, and explore polymerization.

Scholars Program. We would like to thank Andrew and Peggy Cherng and the Panda Charitable Foundation for their gift to this program. Images: . "Structure of Bone Tissue." *Structure of Bone Tissue* | *SEER Training*, U.S. Department of Health and Human Services. 2. "Stem Cell Pathways."*R&D Systems*, R&D Systems.

OOH

 $0 \equiv$

															0 μΜ
															2 μΜ
															5 μΜ
															10 µM
															20 µM
														- 4	40 µM
															75 µM
<u>\</u>															150 µM
															300 µM
															600 uM
															1200 uM
															VEGF
	D	D	CD I	BCD I	A I	AB I	ABC	CDE I	ABC I	EF -	DEF	F	F	F	CDE

Vang & Day, "Advan. and Disadvan. Allograft vs. Autograft". Wichita State University, 2006. 2. Quan et al. Cell. Phys. and Biochem. 46, no. 1 (2018): 401-17.

3. Marrella et al. *Materials Today.* 21, no. 4 (2018): 362-76. 4. Cushnie et al. PLOS ONE. 9, no. 7 (2014). 5. Yasuda et al. *Life Sciences.* 64, no. 4 (1999): 249-58.